Product Information

RISEDRONATE SODIUM 35 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $2.0137 per EA under NDC 59762040504. Its NADAC has been published 354 times since Nov 13, 2019.

FDA first approved this application on Mar 27, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

RISEDRONATE SODIUM 35 MG TABLET

Risedronate Sodium
$2.0137per EA

Strength

30.1; 4.9 mg/1; mg/1

NDC

59762040504

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Authorized Generic (NDA)

FDA Application

NDA020835

FDA Approved

3/27/1998

TE Code

AB

On Market Since

5/17/2002

Pharmacological Classes

Bisphosphonate
Bisphosphonate
Diphosphonates
Diphosphonates

Price Statistics

The NADAC for RISEDRONATE SODIUM 35 MG TABLET has been published 354 times since Nov 13, 2019, and over the history we have for it it has declined 65.4%. The table below summarizes its recorded NADAC range and movement.

Current price$2.0137 per EA
All-time high$5.8238 (Nov 13, 2019)
All-time low$1.1853 (Sep 20, 2023)
52-week high$2.4340
52-week low$1.8164
Median price$2.4265
Average price$2.9329
Largest weekly change+76.8% (Dec 20, 2023)
Weeks tracked354
Tracking sinceNov 13, 2019

Price History

1W

-12.3%

1M

-12.3%

3M

-16.2%

6M

-12.3%

1Y

-15.2%

3Y

+2.0%

5Y

-48.6%

All

-65.4%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of RISEDRONATE SODIUM 35 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for RISEDRONATE SODIUM 35 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $2.0137 per EA (NDC 59762040504), effective Aug 19, 2026.

How has the price of RISEDRONATE SODIUM 35 MG TABLET changed over time?

Over the history we have for it, the NADAC for RISEDRONATE SODIUM 35 MG TABLET has declined 65.4%. It has been tracked across 354 weekly CMS publications since Nov 13, 2019.

What are the highest and lowest recorded NADAC prices for RISEDRONATE SODIUM 35 MG TABLET?

Since Nov 13, 2019, the NADAC for RISEDRONATE SODIUM 35 MG TABLET has ranged from a low of $1.1853 (Sep 20, 2023) to a high of $5.8238 (Nov 13, 2019), with a median of $2.4265 per EA.

Are there cheaper alternatives to RISEDRONATE SODIUM 35 MG TABLET?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RISEDRONATE SODIUM 35 MG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures RISEDRONATE SODIUM 35 MG TABLET?

RISEDRONATE SODIUM 35 MG TABLET (NDC 59762040504) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.